Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby.
Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby. However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus. It is the inability of insulin to absorb the sugars consumed as part of the meal. It may be caused due to insulin resistance in a woman’s body because of increasing levels of placental hormones being produced to sustain the development of the fetus. This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia. According to a case study published by the World Diabetes Foundation, gestational diabetes is an undertreated condition and affects nearly 18 million women each year. It is known to impact over 14% of the pregnancies globally and over 18 million live births every year. Risk factors associated with the condition include overweight babies, risk of developing diabetes mellitus in the later stages of life, birth trauma, respiratory distress, pre-eclampsia, hypocalcemia, and glucose-mediated macrosomia.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35714
The global gestational diabetes treatment market is anticipated to grow during the forecast period driven by increase in prevalence of the condition in the population. According to the American Pregnancy Association, over 2% to 5% of the pregnant women in the U.S. suffer from gestational diabetes, which is likely to rise to 7% to 9% in the near future. Changing lifestyle habits, increasing obesity, delayed pregnancies, and rise in screening for gestational diabetes during prenatal testing contribute to the growth of the market. However, lack of awareness among the people and non-symptomatic nature of the condition are likely to hamper market growth.
Request for Analysis of COVID-19 Impact on Gestational Diabetes Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=35714
The global gestational diabetes treatment market can be segmented based on drug class, mode of administration, distribution channel, and region. In terms of drug class, the market can be categorized into insulin, alpha-glucosidase inhibitors, SGLT-2 inhibitors, and others. Insulin therapy is the most preferred mode of treatment due to its effectiveness in treating the diabetic condition. Based on mode of administration, the global gestational diabetes treatment market can be classified into oral, intravenous, and others. Intravenous mode of administration is mostly preferred owing to the fact that insulin, the commonly employed treatment for gestational diabetes is administered intravenously. In terms of distribution channel, the market can be divided into hospital pharmacies, retail pharmacies, and others.
Pre book Gestational Diabetes Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=35714<ype=S
Geographically, the global gestational diabetes treatment market can be segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America accounted for the largest share of the global market in terms of revenue in 2016. The trend is anticipated to continue during the forecast period. Strong growth in the region can be attributed to rise in prevalence of gestational diabetes among the population and ongoing efforts on spreading awareness among the people. Europe is expected to be the second leading market for gestational diabetes treatment. However, the sluggish economy in the region is likely to negatively impact the growth of the market. The market in Asia Pacific is anticipated to record a significantly high CAGR due to high patient population, rise in government focus on enhancing health care facilities, and increase in product approvals.
Read More Information: https://www.transparencymarketresearch.com/gestational-diabetes-treatment-market.html
Leading players operating in the global gestational diabetes treatment market are Biocon Limited, Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck & Co., Inc., Novartis International AG, Adocia, Peptron, AstraZeneca plc, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., and Abbott Laboratories, among others.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453